Catalyst Pharmaceuticals Appoints New Director
Ticker: CPRX · Form: 8-K · Filed: 2025-01-24T00:00:00.000Z
Sentiment: neutral
Topics: board-appointment, governance
Related Tickers: CPRX
TL;DR
Catalyst Pharma adds Dr. Peterson to the board, effective Jan 17.
AI Summary
Catalyst Pharmaceuticals, Inc. announced on January 17, 2025, a change in its board of directors. Specifically, Dr. Richard J. Peterson has been appointed as a new director, effective immediately. This appointment is part of the company's ongoing efforts to strengthen its governance and strategic oversight.
Why It Matters
The addition of a new director can bring fresh perspectives and expertise to the board, potentially influencing strategic decisions and company direction.
Risk Assessment
Risk Level: low — The filing concerns a routine board appointment, which typically carries low risk.
Key Players & Entities
- Catalyst Pharmaceuticals, Inc. (company) — Registrant
- Dr. Richard J. Peterson (person) — Newly appointed director
- January 17, 2025 (date) — Effective date of appointment
FAQ
Who is Dr. Richard J. Peterson and what is his background?
The filing does not provide specific details about Dr. Richard J. Peterson's background or qualifications, only that he has been appointed as a director.
What is the effective date of Dr. Peterson's appointment?
Dr. Richard J. Peterson's appointment as a director is effective January 17, 2025.
Are there any other changes to the board of directors mentioned in this filing?
This filing specifically details the appointment of Dr. Richard J. Peterson. It does not mention any other departures or appointments.
What is the primary business of Catalyst Pharmaceuticals, Inc.?
Catalyst Pharmaceuticals, Inc. is in the business of pharmaceutical preparations, as indicated by its SIC code [2834].
Where is Catalyst Pharmaceuticals, Inc. headquartered?
Catalyst Pharmaceuticals, Inc. is headquartered in Coral Gables, Florida, with its business address at 355 Alhambra Circle, Suite 801.
From the Filing
0001193125-25-012233.txt : 20250124 0001193125-25-012233.hdr.sgml : 20250124 20250124163014 ACCESSION NUMBER: 0001193125-25-012233 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250117 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250124 DATE AS OF CHANGE: 20250124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 25554574 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d911150d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2025-01-17 2025-01-17     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 17, 2025     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle Suite 801 Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐      If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On January 17, 2025, Charles B. O’Keeffe, an independent member of the Board of Directors (“Board”) of Catalyst Pharmaceuticals, Inc. (the R